Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
5
×
national blog main
biotech
boston blog main
boston top stories
clinical trials
boston
cancer
drugs
fda
national top stories
new york blog main
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
alnylam pharmaceuticals
aminolevulinic acid
arena pharmaceuticals
artificial intelligence
beam therapeutics
biology
biotech week boston
biotechnology
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
broad institute
bwb
cambridge
cannabidiol
cardiovascular disease
cindy perettie
colorectal cancer
crispr
david liu
detroit blog main
detroit top stories
disease
dravet syndrome
What
market
5
×
medicine
5
×
drug
data
fda
patients
pharmaceuticals
series
therapies
ago
alnylam
approved
areas
based
battle
benefiting
biotech
boston
cambridge
cancer
cannabis
cell
cleared
closed
coming
date
derivative
development
diagnostics
eisai
epilepsy
far
february
flags
follows
form
glimcher
groundbreaking
gw
gw’s
Language
unset
Current search:
market
×
medicine
×
" life sciences "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@techcrunch.com
4 years ago
UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon
@xconomy.com
4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug